1Q26 Update: On Track For A Comprehensive Pipeline Update in 2H 2026

Research evidence excerpt

1Q26 Update: On Track For A Comprehensive Pipeline Update in 2H 2026

Biotechnology

BridgeBio Oncology Therapeutics,

Inc. (BBOT)

EQUITY RESEARCH Company Update

May 12, 2026

1Q26 Update: On Track For A Comprehensive Pipeline Price: $8.13

Update in 2H 2026 Rating: Overweight

Key Statistics: BBOT reported 1Q26 earnings this evening with no major surprises. The Symbol NASDAQ: BBOT

52-Week Range 7.60 - 14.87 company continues to make progress across its three clinical-stage RAS-

Market Cap 651.3 pathway inhibitor programs, with clinical updates expected across the

ADV (3 mo) 318,767 portfolio in 2H26.

Shares Out (M) 80.1

●See our initiation report (HERE) for the full rundown on BBOT's

Research Analysts: pipeline, as well as a recap of the company's Phase 1 data updates

Eric Schmidt from earlier this year (HERE).

212-294-7724

Eric.Schmidt@cantor.com Recall, BBOT is developing three potentially first- and best-in-class drugs

Imogen Mansfield that target the RAS pathway, including ON/OFF inhibitors of KRAS, and a

929-545-6495 novel inhibitor of PI3Kα. Imogen.Mansfield@cantor.com

Tim Samuel, PhD ●BBO-8520 is a KRASG12C (ON/OFF) inhibitor designed to achieve 212-294-7962

Tim.Samuel@cantor.com deeper KRASG12C inhibition, while improving combinability with

pembrolizumab.

REV ($M)

FYE Dec 2025A 2026E 2027E ●In January, the company reported encouraging Phase 1

1Q $0.0 $0.0E $0.0 monotherapy activity in KRASG12C NSCLC, including 65% ORR and

2Q $0.0 $0.0E $0.0 68% 6-month PFS (n=17), along with early pembro combo data

3Q $0.0 $0.0E $0.0 suggesting a potentially differentiated liver toxicity profile (n=15 4Q $0.0 $0.0E $0.0

Year $0.0 $0.0E $0.0 safety / n=8 efficacy).

EPS ●Updated pembro combo data are expected in 2H26.

FYE Dec 2025A 2026E 2027E

1Q - $(0.53)A -